

13 March 2019



RESPIRI ANNOUNCES IR APPOINTMENT

The Board of Respiri Limited (ASX:RSH), is pleased to announce the appointment of Mr Gerry Bullon as Investor Relations consultant and market interface for the Company.

As Respiri moves towards commercialisation of its unique and innovative wheezo™ respiratory monitoring ecosystem the Board looks forward to continuing to expand clinical, consumer and investor awareness of Respiri's opportunity to capitalise on the global opportunity to provide a much needed new self-monitoring technology for patients suffering from the chronic diseases of asthma and COPD.

Mr Bullon brings twenty-three years of IR and management consulting experience with the majority of his work as principal of INSOR (www.insor.com.au).

He has specialised in assisting small and mid-cap companies grow their broker research coverage, and in growing institutional investment.

Previously, Mr Bullon has facilitated the public listings of Australian Hospital Care (AHX), Sigma Pharma (SIG), Nick Scali (NCK) and Probiotec (PBP). He has also advised real-estate.com (REA) for four years.

Mr Bullon is now a Non-Executive Director of SDI Limited (SDI), a Director of Longevity Group Australia, a public unlisted company, and more recently has become Non-Executive Director of Rounded and recstra, and Solo Cover, app-based start up companies, and Chairman of Beames Capital that helps fund those businesses.

Mr Bullon is a Fellow of the Australian Institute of Company Directors.

The Board has decided to delay the proposed March conference call referred to in a previous ASX announcement for approximately two weeks in order for Mr Bullon to come on board and provide his expertise and assistance in expanding our investor reach.

--END--

Contact:

Mario Gattino

CEO

+61 3 9653 9160

About Respi Limited

Respi's mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respi's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respi Limited's operations are based in Melbourne, Australia.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respi's current expectations, estimates and projections about the industry in which Respi operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respi, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respi cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respi only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respi will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

